Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05853848
Other study ID # 2022-0369
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 10, 2023
Est. completion date June 2024

Study information

Verified date June 2023
Source Geisinger Clinic
Contact Amir Goren, PhD
Phone 5702144395
Email agoren@geisinger.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The project aims to evaluate four different versions and modalities of interventions encouraging mammogram screening among all eligible women due or overdue for screening. The evaluation will compare among the following forms of outreach to help determine whether (a) live calls are more effective at increasing mammogram screening than other forms of outreach and (b) each form of outreach is more effective than no outreach: (1) a postcard, (2) a letter, (3) an auto-dialer phone message, and (4) a live call from a care gaps team. The interventions will be rolled out over many months, allowing for comparisons of effectiveness against those who have not yet been contacted.


Recruitment information / eligibility

Status Recruiting
Enrollment 17650
Est. completion date June 2024
Est. primary completion date June 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 51 Years to 74 Years
Eligibility Inclusion Criteria: - Female Geisinger Health Plan members between ages 52 and 74 as of December 31, 2023 - Overdue for annual mammogram - Continuously enrolled with the Geisinger Health Plan as of October 1, 2021 - Can be contacted via both phone and mail Exclusion Criteria: - Geisinger Health Plan members on a do-not-contact list - Had a mammogram as of October 1, 2021 - In hospice, using hospice services, or receiving palliative care as of January 1, 2023 - Medicare members 66 years of age or above at time of outreach, who are institutionalized or have both frailty and advanced illness - Had a bilateral mastectomy at any time

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Postcard
Postcard with phone number to call for help scheduling a mammogram.
Letter
Letter with phone number to call for help scheduling a mammogram.
Auto-dialer
Auto-dialer with option to press button for help scheduling a mammogram.
Live call
Live call offering help scheduling a mammogram.

Locations

Country Name City State
United States Geisinger Danville Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Geisinger Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Mammogram completed Record of completed mammogram (yes/no), for comparing across postcards, letters, and auto-dialer messages In the 180 days following the patient's intervention send date
Other Breast malignancy risk detected Record of high malignancy risk (yes/no), for comparing across different modalities of outreach In the 210 days following the patient's intervention send date
Other Mammogram appointment scheduled Appointment scheduled for mammogram, among patients visiting Geisinger clinics (yes/no) In the 30 days following the patient's intervention send date
Primary Mammogram completed Record of completed mammogram (yes/no), for comparing postcards, letters, and auto-dialer messages with live calls In the 180 days following the patient's intervention send date
Primary Mammogram completed Record of completed mammogram (yes/no), for comparing postcards, letters, auto-dialer messages, and live calls with controls In the 120 days following the patient's intervention send date
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A